Advanced search×

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.

Nat Genet 40(5):499-507 (2008) PMID 18443585

Cancer cells possess traits reminiscent of those ascribed to normal stem cells. It is unclear, however, whether these phenotypic similarities reflect the activity of common molecular pathways. Here, we analyze the enrichment patterns of gene sets associated with embryonic stem (ES) cell identity in the expression profiles of various human tumor types. We find that histologically poorly differentiated tumors show preferential overexpression of genes normally enriched in ES cells, combined with preferential repression of Polycomb-regulated genes. Moreover, activation targets of Nanog, Oct4, Sox2 and c-Myc are more frequently overexpressed in poorly differentiated tumors than in well-differentiated tumors. In breast cancers, this ES-like signature is associated with high-grade estrogen receptor (ER)-negative tumors, often of the basal-like subtype, and with poor clinical outcome. The ES signature is also present in poorly differentiated glioblastomas and bladder carcinomas. We identify a subset of ES cell-associated transcription regulators that are highly expressed in poorly differentiated tumors. Our results reveal a previously unknown link between genes associated with ES cell identity and the histopathological traits of tumors and support the possibility that these genes contribute to stem cell-like phenotypes shown by many tumors.

DOI: 10.1038/ng.127
Version: za2963e q8za6 q8zb0 q8zcc q8zd4 q8ze6 q8zf2 q8zg0

Similar articles you may find interesting…

  1. Cancer: a "stem-cell" disease?

    Cancer Cell Int 13(1):40 (2013) PMID 23647946

    We believe that cancer is a genetic disease. We focus on the genetic targets and epigenetic changes in a tumor. Remarkably, many crucial signal pathways in a malignant cell involve "stem-ness" genes. The prevalence of stem-ness in cancer suggests that cancer has a stem-cell origin and is a stem-cell...
  2. Engineering bone tissue substitutes from human induced pluripotent stem cells.

    Proc Natl Acad Sci U S A (2013) PMID 23653480

    We first induced three hiPSC lines with different tissue and reprogramming backgrounds into the mesenchymal lineages and used a combination of differentiation assays, surface antigen profiling, and global gene expression analysis to identify the lines exhibiting strong osteogenic differentiation pot...
  3. Potential for pharmacological manipulation of human embryonic stem cells

    Br J Pharmacol 169(2):269-289 (2013) PMID 22515554

    We hope to describe the current uses of small molecule inhibitors/activators in hESC biology and their potential uses in the future. © 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society. © 2012 The Authors. British Journal of Pharmacology...